Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1673-1678

  Scholz, Mark C ^a   Jennrich, Robert I ^a   Strum, Stephen B ^a   Johnson, Henry J ^a   Guess, Brad W ^a   Lam, Richard Y ^a  

^a Department of Statistics ^*  (United States)

Author keywords

finasteride androgen antagonists; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER RELAPSE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; SCORING SYSTEM; TIME;

AGED; AGED, 80 AND OVER; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS;

EID: 33645970181     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00975-4     Document Type: Article

References (20)

1. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D., et al. Effects of intermittent androgen suppression on androgen-dependent tumors. apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782
2. Schasfoort E., Heathcote P., Lock T., Zerbib M., Dijkema M., Vergunst H., et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 169 suppl (2003) 1483 397
3. Tunn U.W., Eckart O., Offenbach D.E., Kienle E.F., Hillger H., and Aachen D.E. Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase-III clinical trial EC 507. J Urol 169 suppl. (2003) 396 abstract 1481
4. Andriole G., Lieber M., Smith J., Soloway M., Schroeder F., Kadmon D., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45 (1995) 491
5. Kirby R., Robertson C., Turkes A., Griffiths K., Denis L.J., Boyle P., et al., International Prostate Health Council (IPHC) Trial Study Group. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. Prostate 40 (1999) 105
6. Kaplan S.A., Ghafar M.A., Volpe M.A., Lam J.S., Fromer D., Te A.E., et al. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy. preliminary study. Urology 60 (2002) 464
7. Tay M.H., Kaufman D.S., Regan M.M., Leibowitz S.B., George D.J., Febbo P.G., et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 15 (2004) 974
8. Thompson I.M., Goodman P.J., Tangen C.M., Tangen C.M., Lucia M.S., Parnes H.L., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
9. Scardino P.T. The prevention of prostate cancer-the dilemma continues. N Engl J Med 349 (2003) 297
10. Bostwick D.G., Qian J., Civantos F., Roehrborn C.G., and Montironi R. Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer 2 (2004) 228
11. Carver S.C., Kattan M.W., Scardino P.T., and Eastham J.A. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 95 (2005) 509
12. Al-Azub K.R., Lockwood G., Toi A., Jewett M.A., Trachtenberg J., and Fleshner N. Evidence for a biopsy-derived grade artifact among larger prostate glands. implications for the prostate cancer prevention trial. J Urol 173 suppl. (2005) 70 abstract 254
13. Roehrborn C.G. Letter to the editor. prevention of prostate cancer with finasteride. New Engl J Med 349 (2003) 1569
14. Andriole G.L., Guess H.A., Epstein J.I., Wise H., Kadmon D., Crawford E.D., et al., PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer. results of a randomized, double-blind, placebo-controlled clinical trial. Urology 52 (1998) 195
15. Scholz M.C., Trilling T., Brosman S.A., Guess B.W., Johnson H.J., and Lam R.Y. PSA nadir greater than 0.1 on combined hormone blockade predicts the early development of androgen independent prostate cancer in men with PSA relapse after local therapy. Presented at meeting of Western Section, American Urological Association (2003) abstract 09-43
16. Nejat R.J., Rashid H.H., Bagiella E., Katz A.E., and Benson M.C. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891
17. Pickles T., Agranovich A., Berthelet E., Duncan G.G., Keyes M., Kwan W., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362
18. De La Taille A., Zerbib M., Conquy S., Amsellem-Ouazana D., Thiounn N., Flam T.A., et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 91 (2003) 18
19. Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., Ito H., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer. preliminary report of a prospective multicenter study. Urology 64 (2004) 341
20. Wessells H., Roy J., Bannow J., Grayhack J., Matsumoto A.M., Tenover L., et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61 (2003) 579